Efficacy of different doses of Buprenorphine on reduction of withdrawal symptoms, anxiety, depression and suicidal thoughts
Phase 4
Recruiting
- Conditions
- Opioid dependency.Mental and behavioral disorders due to use of opioids
- Registration Number
- IRCT2017071925160N6
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 60
Inclusion Criteria
Inclusion Criteria:age between 16 to 60 y/o; informed consent;Opioid dependence Exclusion criteria:Patients unwilling to participate at beginning or during the study; use of other substances except Opioid as of the main substance
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Withdrawal symptoms in opioid dependents. Timepoint: before the first dose and first day to 4 days. Method of measurement: Interview and questionnaire.
- Secondary Outcome Measures
Name Time Method Anxiety, depression in opioid dependents. Timepoint: Before the first dose and first day to 4 days. Method of measurement: Interview and questionnaires.